Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $395.06 million. The enterprise value is $354.92 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 228.36 million shares outstanding. The number of shares has increased by 22.42% in one year.
| Current Share Class | 228.36M |
| Shares Outstanding | 228.36M |
| Shares Change (YoY) | +22.42% |
| Shares Change (QoQ) | +1.02% |
| Owned by Insiders (%) | 5.43% |
| Owned by Institutions (%) | 20.90% |
| Float | 166.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 35.01 |
| Forward PS | 20.93 |
| PB Ratio | 8.16 |
| P/TBV Ratio | 65.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.08 |
| Quick Ratio | 3.96 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -71.51% and return on invested capital (ROIC) is -21.41%.
| Return on Equity (ROE) | -71.51% |
| Return on Assets (ROA) | -13.17% |
| Return on Invested Capital (ROIC) | -21.41% |
| Return on Capital Employed (ROCE) | -25.48% |
| Revenue Per Employee | $141,740 |
| Profits Per Employee | -$531,299 |
| Employee Count | 77 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +104.86% in the last 52 weeks. The beta is 1.77, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | +104.86% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 51.15 |
| Average Volume (20 Days) | 1,972,002 |
Short Selling Information
The latest short interest is 31.77 million, so 13.91% of the outstanding shares have been sold short.
| Short Interest | 31.77M |
| Short Previous Month | 27.75M |
| Short % of Shares Out | 13.91% |
| Short % of Float | 19.10% |
| Short Ratio (days to cover) | 17.21 |
Income Statement
In the last 12 months, LCTX had revenue of $10.91 million and -$40.91 million in losses. Loss per share was -$0.19.
| Revenue | 10.91M |
| Gross Profit | -2.17M |
| Operating Income | -20.40M |
| Pretax Income | -40.76M |
| Net Income | -40.91M |
| EBITDA | -19.77M |
| EBIT | -20.40M |
| Loss Per Share | -$0.19 |
Full Income StatementBalance Sheet
The company has $42.29 million in cash and $2.15 million in debt, giving a net cash position of $40.13 million or $0.18 per share.
| Cash & Cash Equivalents | 42.29M |
| Total Debt | 2.15M |
| Net Cash | 40.13M |
| Net Cash Per Share | $0.18 |
| Equity (Book Value) | 47.11M |
| Book Value Per Share | 0.21 |
| Working Capital | 33.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.56 million and capital expenditures -$588,000, giving a free cash flow of -$23.15 million.
| Operating Cash Flow | -22.56M |
| Capital Expenditures | -588,000 |
| Free Cash Flow | -23.15M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
| Gross Margin | -19.86% |
| Operating Margin | -186.87% |
| Pretax Margin | -373.45% |
| Profit Margin | n/a |
| EBITDA Margin | -181.13% |
| EBIT Margin | -186.87% |
| FCF Margin | n/a |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.42% |
| Shareholder Yield | -22.42% |
| Earnings Yield | -10.36% |
| FCF Yield | -5.86% |
Dividend DetailsAnalyst Forecast
The average price target for LCTX is $4.25, which is 145.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.25 |
| Price Target Difference | 145.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 57.08% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
LCTX has an Altman Z-Score of -4.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.91 |
| Piotroski F-Score | 4 |
